ScreenerHero

LYRALyra Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · lyratherapeutics.com
0.0004USD-98.87%Mkt Cap: 709 $P/E: —

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap709 $
Enterprise Value14.37M $
Revenue (TTM)398.00K $
Gross Profit-608.00K $
Net Income (TTM)-28.92M $
Revenue/Share0.2560 USD
Last Price0.0004 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees27
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA-0.49
EV/Revenue36.10
P/S0.00
P/B-0.00
EPS (TTM)-18.62
EPS (Forward)-0.99
52W Range
0.00040% of range8.748
52W High8.748 USD
52W Low0.0004 USD
Profitability
Gross Margin-152.76%
Oper. Margin-98728.57%
EBITDA Margin0.00%
Profit Margin-7266.08%
ROE269.84%
ROA-80.09%
Growth
Revenue Growth-96.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.86M $
CapEx (TTM)116.00K $
FCF Margin-4404.43%
FCF Yield-2472443.44%
Net Debt14.37M $
Net Debt/EBITDA-0.49
Balance Sheet
Debt/Equity-2.82
Current Ratio1.71
Quick Ratio1.67
Book Value/Sh-6.0380 USD
Cash/Share8.954 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMay 28, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.77M
Float440.19K
Insiders0.62%
Institutions6.67%
Short Interest
Short Ratio0.3d
Short % Float1.10%
Short % Out.0.93%
Shares Short16.53K
Short (prev mo.)59.09K
Technical
SMA 500.4840 (-99.9%)
SMA 2001.436 (-100.0%)
Beta0.70
S&P 52W Chg18.16%
Avg Vol (30d)3.54K
Avg Vol (10d)2.06K
Technical Indicators
RSI (14)14.2
MACD-0.1185
MACD Signal-0.0827
MACD Hist.-0.0357
BB Upper0.6912 USD
BB Middle0.3718 USD
BB Lower0.0523 USD
BB Width171.84%
ATR (14)0.0848 USD
Vol Ratio (20d)0.74x